Compare PulteGroup, Inc. (PHM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs TG Therapeutics Inc — how do they compare? PulteGroup, Inc. trades at $111.91 (market cap $21.63B), while TG Therapeutics Inc trades at $54.84 (market cap $8.16B). The key difference: PulteGroup, Inc. is far larger — about 2.7× TG Therapeutics Inc's market cap, and PulteGroup, Inc. pays a 0.92% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PulteGroup, Inc. for 91 Days and TG Therapeutics Inc for 16 Days on average.
| PHM | TGTX | |
|---|---|---|
Market Cap | $21.63B | $8.16B |
Volume | 2,324,729 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $59.06 |
52-Week Low | $110.11 | $26.94 |
Typical Hold Time | 91 Days | 16 Days |
Enterprise Value | $22.04B | $8.37B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $111.76, down 0.51% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with support near $109-110, while fundamentals reveal solid profitability (11.62% net margin) but declining revenue and earnings trends. Recent quarters show mixed earnings performance with two misses and one beat against expectations.
PHM presents a value opportunity with attractive valuation multiples (P/E 11.6) and analyst consensus target of $139.80, but faces headwinds from housing affordability concerns and volatile cash flows. The stock's near-term trajectory depends on Q3 2026 earnings results due October 22, 2026, with institutional ownership remaining stable despite sector challenges.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
